Why the study?
Does the use of antidepressants and/or statins reduce major adverse cardiovascular events in patients without prior CVD, and does this effect vary by depression severity?
Does the use of antidepressants and/or statins reduce major adverse cardiovascular events in patients without prior CVD, and does this effect vary by depression severity?
The cardiovascular benefit of statins and antidepressants varies by depression severity, with statins showing benefit in mild depression and antidepressants showing benefit in moderate-severe depression.
Answers are grounded in this paper and cite their sources.
Should not yet change primary prevention practice; hypothesis-generating for depression-stratified outcome trials.
Depression has been reported to be associated with a greater risk of death and cardiovascular disease (CVD); however, the impact of antidepressants (ADM) on CVD risk remains controversial. Statin use is known to decrease CVD risk. Whether the use of these medications together affects CVD risk has not been studied. Patients (N = 26,828) completing the patient health questionnaire (PHQ-9), ≥40 years of age, without prior CVD, and no prior ADM use were studied. Depressive severity was categorized as none-mild (PHQ-9 score ≤14, n = 21,517) and moderate-severe (PHQ-9 score ≥15, n = 5311). Cox hazard regression was used to evaluate the association of no ADM/no statin use (n = 23,104 [86.1%]), ADM/no statin use (n = 877 [3.3%]), no ADM/statin use (n = 2627 [9.8%]), and ADM/statin use (n = 220 [.8%]) with major adverse cardiovascular events (MACE: death, CAD, stroke). Patients averaged 56 ± 12 years; 61% female. There were 1182 (4.4%) 3 year MACE events. The association of ADM and statin use with MACE varied by depressive symptom severity, with statin therapy associated with a decreased risk in the none-mild group (HR = .78, p = .007) and ADM in the moderate-high group (HR = 0.58, p = 0.02). Concomitant use of ADMs and statins did not appear to provide additive benefit.
No takes yet. Share an insight, caveat, or question.
May et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: